Olivas-Vergara Otto M, Hernanz Inés, Borges-Deniz Pablo E, Romero-Bueno Fredeswinda, Sanchez-Pernaute Olga, Carreño Ester
Rheumatology Department, Fundación Jiménez Díaz University Hospital, Madrid, Spain.
Ophthalmology Department, Fundación Jiménez Díaz University Hospital, Madrid, Spain.
Front Ophthalmol (Lausanne). 2025 Feb 27;5:1491981. doi: 10.3389/fopht.2025.1491981. eCollection 2025.
Secukinumab is a monoclonal antibody that selectively neutralizes interleukin-17A and has shown efficacy in the treatment of psoriatic arthritis, psoriasis, and axial spondyloarthritis. Its use in non-anterior non-infectious uveitis is controversial, with evidence generally not supporting its effectiveness in these conditions. However, the role of secukinumab in anterior non-infectious uveitis remains unclear.
Case series. Five patients with biological therapy-refractory non-infectious anterior uveitis who were treated with secukinumab were included.
All 5 patients experienced a uveitis flare-up during treatment, and secukinumab failed to induce long-term remission in 2 of these patients, who also had uncontrolled systemic disease.
Secukinumab failed to prevent uveitis flare-up in these patients with biological therapy-refractory disease. Further studies are necessary to determine the potential role of secukinumab in the treatment of anterior uveitis.
司库奇尤单抗是一种选择性中和白细胞介素-17A的单克隆抗体，已显示出在治疗银屑病关节炎、银屑病和中轴型脊柱关节炎方面的疗效。其在非前部非感染性葡萄膜炎中的应用存在争议，一般证据不支持其在这些病症中的有效性。然而，司库奇尤单抗在前部非感染性葡萄膜炎中的作用仍不清楚。
病例系列。纳入了5例接受司库奇尤单抗治疗的生物治疗难治性非感染性前部葡萄膜炎患者。
所有5例患者在治疗期间均出现葡萄膜炎复发，其中2例患者司库奇尤单抗未能诱导长期缓解，这2例患者还患有未得到控制的全身性疾病。
司库奇尤单抗未能预防这些生物治疗难治性疾病患者的葡萄膜炎复发。需要进一步研究以确定司库奇尤单抗在治疗前部葡萄膜炎中的潜在作用。
